Robert Siegel is currently the Vice President at Eli Lilly and Company, where they manage a recombinant antibody program. Siegel's career has predominantly focused on in vitro display systems for antibody engineering, including work at Abbott Laboratories and as a Senior Research Scientist at Eli Lilly. Previously, Siegel developed a yeast program at the Pacific Northwest National Laboratory and conducted postdoctoral research at Los Alamos National Laboratory under Dr. Andrew Bradbury. Siegel holds a Ph.D. in Microbiology/Biochemistry from Indiana University Bloomington and a B.S. in Life Sciences from Indiana State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices